Quantiferon-TB Gold in the Assessment of Latent TB in Patients Candidate to Treatment or Treated With TNFα Antagonists (TNFTB)
Recruitment status was: Recruiting
Procedure: Quantiferon-TB Gold assay
Procedure: Tuberculin skin test
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
|Official Title:||Comparison of Quantiferon-TB Gold Assay With Tuberculin Skin Testing in the Assessment of Latent Mycobacterium Tuberculosis Infection in Patients Candidate to Treatment or Treated With TNFα Antagonists|
- Concordance between the QFT-G assay and the tuberculin skin test
- Correlation of the test results to the patient’s risk of LTBI
- Factors associated with discordance between the TST and the QFT-G test
- Frequency of indeterminate results
|Study Start Date:||June 2007|
|Estimated Study Completion Date:||October 2007|
Treatment with TNFα antagonists is associated with an increased risk of active tuberculosis. Screening for LTBI and adherence to published guidelines have been shown to greatly decrease the risk of active tuberculosis. However, the best screening strategy is still object of debate. The validity of TST in patients on immunosuppressive treatment has been questioned. Recently, interferon-γ assays based on RD1-specific antigens have shown to cause less confounding by BCG vaccination and from most non-tuberculosis mycobacteria than TST, and have shown improved accuracy over TST in several settings. However, data on their use in rheumatologic patients are limited, and their superiority in patients on immunosuppressive treatment is unclear since indeterminate results may limit their clinical usefulness in this setting.
Purpose of the study is to investigate the added value of the inclusion of QTF-G assay in the screening strategy of LTBI in rheumatologic patients before and during treatment with TNFα antagonists.
The study will compare the results of TST with the results of QFT-G assay in rheumatologic patients being evaluated for treatment with anti-TNFα agents or already on treatment with anti-TNFα agents. The rate of positive and negative results of the two test will be compared, end results correlated to clinical and demographic variables.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00491933
|Contact: Marco Antivalle, MD||+39023904 ext firstname.lastname@example.org|
|Contact: Luca Bertani, MD||+39023904 ext email@example.com|
|Rheumatology Unit, Ospedale L. Sacco Polo Universitario||Recruiting|
|Milano, Italy, 20157|
|Principal Investigator:||Marco Antivalle, MD||Ospedale L. Sacco - Polo Universitario, Milano, Italy|